Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - live attenuated oka/merck strain of varicella-zoster virus - powder and solvent for suspension for injection - live attenuated oka/merck strain of varicella-zoster virus 19400 pfu / 0.65 ml - zoster, live attenuated - zoster, live attenuated - zostavax is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older.

European Union - English - EMA (European Medicines Agency)

laboratorios hipra s.a - live ge- tk- double-gene-deleted bovine herpes virus type 1, strain ceddel: 106.3–107.3 ccid50 - immunologicals - cattle - for the active immunisation of cattle from three months of age against bovine herpes virus type 1 (bohv-1) to reduce the clinical signs of infectious bovine rhinotracheitis (ibr) and field virus excretion.onset of immunity: 21 days after completion of the basic vaccination scheme.duration of immunity: 6 months after completion of the basic vaccination scheme

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - live newcastle disease virus clone 30 - lyophilisate for oculonasal suspension/use in drinking water - . - newcastle disease virus / paramyxovirus - chickens, turkeys - immunological - live vaccine

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - live aroa-gene deleted escherichia coli,type o78,ec34195 - unknown - live aroa-gene deleted escherichia coli,type o78,ec34195 vaccine-microbial active 0.0 - active constituent

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg; leucine, quantity: 0.432 mg - injection, powder for - excipient ingredients: lactose; sorbitol; mannitol; threonine; serine; proline; glycine; alanine; valine; methionine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg - injection, powder for - excipient ingredients: lactose; mannitol; sorbitol; threonine; serine; proline; glycine; alanine; valine; methionine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml - injection, powder for - excipient ingredients: lactose; mannitol; sorbitol; threonine; serine; proline; glycine; alanine; valine; methionine; isoleucine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immuncompromised patients with no history of the disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 19400 pfu - injection, powder for - excipient ingredients: dibasic sodium phosphate; sodium chloride; urea; potassium chloride; sucrose; monobasic potassium phosphate; monosodium glutamate monohydrate; hydrolysed gelatin - zostavax is indicated for the prevention of herpes zoster (shingles) in individuals 50 years of age and older. zostavax is indicated for the prevention of postherpetic neuralgia (phn) and for reduction of acute and chronic zoster-associated pain in individuals 60 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 19400 pfu - injection, powder for - excipient ingredients: monosodium glutamate monohydrate; sodium chloride; sucrose; hydrolysed gelatin; dibasic sodium phosphate; monobasic potassium phosphate; potassium chloride; urea - zostavax is indicated for the prevention of herpes zoster (shingles) in individuals 50 years of age and older. zostavax is indicated for the prevention of postherpetic neuralgia (phn) and for reduction of acute and chronic zoster-associated pain in individuals 60 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 19400 pfu - injection, powder for - excipient ingredients: monosodium glutamate monohydrate; monobasic potassium phosphate; urea; sodium chloride; dibasic sodium phosphate; hydrolysed gelatin; potassium chloride; sucrose - zostavax is indicated for the prevention of herpes zoster (shingles) in individuals 50 years of age and older. zostavax is indicated for the prevention of postherpetic neuralgia (phn) and for reduction of acute and chronic zoster-associated pain in individuals 60 years of age and older.